查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2093321

免疫腫瘤臨床試驗市場－2026-2032年全球市場預測

Immuno-oncology Clinical Trials Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，免疫腫瘤學臨床試驗市場將成長至 194.7 億美元，複合年成長率為 14.81%。

主要市場統計數據
基準年 2025 74億美元
預計年份：2026年 83.2億美元
預測年份 2032 194.7億美元
複合年成長率 (%) 14.81%

免疫腫瘤學臨床試驗正在透過評估活化、恢復或重新誘導免疫系統對抗腫瘤的療法，改變癌症研究的格局，這些療法包括免疫查核點抑制劑、細胞療法、癌症疫苗、雙特異性抗體、細胞激素療法和聯合治療。臨床試驗的發展趨勢日益呈現出以下特徵：基於生物標記的受試者招募、適應性方案設計、真實世界數據（REW）的整合、分散式試驗要素以及針對免疫相關不利事件的更先進的安全性監測。監管機構強調科學合理的終點、具有代表性的患者群體、檢驗的診斷方法以及透明的風險獲益評估的重要性，尤其是在臨床試驗進入治療早期和手術全期。在整體腫瘤學領域，臨床研發的挑戰正從單一療法評估轉向合理的聯合治療、腫瘤非依賴性策略、微量殘存疾病監測以及基於基因組學、轉錄組學、蛋白質組學和免疫分析數據的個人化免疫療法。對於贊助商、臨床實驗研究員、合約研究合作夥伴、學術網路和醫療保健系統而言，如今的成功取決於科學差異化與卓越營運、患者准入、符合倫理的受試者招募、數據品質和監管準備的一致性。

免疫腫瘤學臨床試驗環境的變革性變化

隨著研究從廣泛的腫瘤類型入組轉向精準免疫學，免疫腫瘤學臨床試驗的模式正在經歷一場變革性的轉變。試驗方案擴大納入PD-L1表達、微衛星不穩定性、錯配修復缺陷、腫瘤突變負荷、同源重組修復狀態、 HLA型檢測、循環腫瘤DNA和免疫微環境特徵等指標，以識別最有可能獲益的患者群體。免疫檢查查核點抑制劑、標靶治療、化療、放射線治療、抗體藥物複合體（ADC）、雙特異性抗體、溶瘤病毒和過繼性細胞療法等聯合治療研究的擴展，對方案管治和不利事件管理提出了更高的要求。為了在保持統計學嚴謹性的同時加快決策速度，研究人員正在採用適應性強且無縫銜接的試驗設計，並透過主方案支援在通用基礎設施內評估多種藥物、生物標記或腫瘤群。此外，以患者為中心的臨床試驗正在蓬勃發展，尤其是在腫瘤長期隨訪方面，遠端知情同意、遠距遠端醫療諮詢、居家護理、數位化患者報告結局（PRO）以及混合監測模式等措施得到了廣泛應用。同時，監管機構和倫理委員會也更加重視多元化、公平取得、在適當情況下納入兒童和老年人以及試驗後證據的收集。這些變化使得免疫腫瘤學臨床試驗在科學上更具雄心，在操作上更具挑戰性，並且在策略上更加依賴整合的臨床、轉化、數位化和監管能力。

人工智慧對免疫腫瘤臨床試驗的累積影響

人工智慧 (AI) 對免疫腫瘤臨床試驗的各個方面都產生了日益顯著的影響，包括可行性評估、中心選擇、患者識別、影像分析、生物標記發現、安全性監測和試驗管理。 AI 驅動的篩檢工具可以利用電子健康記錄、病理報告、分子實驗室結果和臨床記錄，幫​​助將患者與合格標準進行匹配，從而提高受試者招募的準確性，同時減輕人工預篩檢的負擔。在轉化研究中，機器學習模型正被應用於多體學資料集、空間生物學、放射組學和免疫定序，以推進對反應特徵和抗藥性機制的識別。 AI 驅動的醫學影像工作流程有助於量化與反應評估相關的影像模式，包括腫瘤負荷、病灶動態變化以及假性進展等非典型免疫反應。自然語言處理和先進的分析技術也透過從結構化和非結構化資料中識別免疫相關不利事件的訊號，從而增強藥物警戒。然而，人工智慧的累積影響取決於經過檢驗的演算法、有針對性的資料集、可解釋性、網路安全、偏差緩解以及對不斷變化的數位健康技術和基於軟體的臨床決策支援監管要求的遵守情況。對於免疫腫瘤臨床試驗的相關人員，人工智慧最好被視為一種“增強層”，它可以提高速度、一致性和洞察力，而人類的臨床判斷、倫理監督和方案規定的證據標準仍然至關重要。

全球免疫腫瘤臨床試驗的關鍵區域見解

由於亞太地區癌症診療基礎設施不斷完善、未接受治療的患者數量龐大、分子診斷能力不斷提升，以及中國、日本、韓國、印度和澳洲等國積極推進監管現代化，該地區正成為免疫腫瘤學臨床試驗的關鍵區域。該地區在固體癌和骨髓惡性腫瘤領域進行廣泛的研究，特別關注胃癌、肝癌、肺癌、頭頸癌、乳癌和大腸癌。這反映了該地區的疾病負擔、篩檢趨勢以及主要癌症中心對次世代定序的日益普及。北美地區在免疫電子健康記錄健康記錄基礎設施以及完善的監管途徑，這些都為滿足未被滿足的醫療需求提供了快速開發所需的臨床證據。拉丁美洲也以其在巴西、墨西哥、阿根廷、智利和哥倫比亞的腫瘤中心而日益重要。在這些地區，多樣化的患者群體和不斷提升的臨床研究能力為參與全球臨床試驗提供了支持，但核准流程、保險報銷、分子檢測以及試驗中心資源等方面的差異，使得周密的運營規劃至關重要。在歐洲，學術腫瘤學團隊組成的緊密生態系統、歐盟統一的臨床試驗法規以及強大的生物標記科學、真實世界數據和療效比較研究能力已然形成，其中英國、德國、法國、義大利和西班牙是多中心免疫療法研究的主要貢獻者。在中東，透過對三級醫療、精準醫療計畫、癌症登記處和跨國研究合作的投資，癌症臨床試驗的進行能力正不斷提升。這一趨勢在海灣國家尤為顯著，這些國家擁有先進的醫院基礎設施和國家醫療衛生轉型策略。在非洲，儘管癌症負擔沉重且具有豐富的遺傳多樣性，免疫腫瘤學家參與臨床試驗的程度仍然不足。取得進展需要對病理學、影像學、分子診斷、倫理審查系統、臨床實驗研究者培訓、藥物安全監測體係以及公平參與臨床試驗的機會進行持續投入。在所有地區，最成功的免疫腫瘤學臨床試驗計畫都力求使方案的複雜性與當地的診斷能力、患者就診流程、監管時間表、免疫相關毒性管理以及長期追蹤的可行性相符。

小組對免疫腫瘤學臨床試驗策略的主要觀點

東協成員國，包括新加坡、泰國、馬來西亞、越南、印尼和菲律賓，正在加強癌症醫療網路建設，引入分子檢測，建立癌症登記系統，並促進區域間研究合作，在免疫腫瘤學臨床試驗中發揮日益重要的作用。然而，倫理審查流程、基礎設施、保險報銷以及先進診斷技術的取得等方面的差異，影響試驗的可行性。海灣合作理事會（GCC）成員國正透過國家癌症戰略、三級癌症中心、基因組醫學舉措、數位健康投資以及集中式醫療現代化建設，提升臨床試驗能力，為精心設計的免疫療法試驗創造機遇，以應對區域特有的癌症模式挑戰，並促進區域內循證醫學證據的產生。歐盟在統一的臨床試驗法規架構下，為多邊癌症臨床試驗提供了一個系統性的環境，並輔以健全的藥物安全監測標準、健康數據管治、隱私保護和學術合作網路。因此，歐盟在生物標記主導的、比較性的以及上市後證據研究中發揮著尤為重要的作用。金磚國家擁有多元化的醫療健康體系和大規模的癌症病患群體。中國和印度在臨床試驗活動方面處於領先地位，巴西和南非則在地域分佈廣泛的受試者招募方面做出了貢獻，而俄羅斯儘管面臨地緣政治和運營方面的複雜性，需要進行謹慎的風險評估，但仍保持著專業的腫瘤學研究能力。七國集團（G7）透過先進的監管體系、大規模癌症研究機構、成熟的衛生技術評估框架以及在轉化腫瘤學、診斷、臨床數據標準和真實世界數據應用方面的領先地位，持續影響全球免疫腫瘤學臨床試驗標準。北約成員國與成熟的北美和歐洲臨床研究生態系統高度重疊，在這些地區，臨床實驗管治、數據安全、供應鏈韌性、臨床實驗藥物物流和跨境研究協調在複雜的免疫腫瘤學研究中尤為關鍵。在所有這些群體中，成功的決定性因素不僅包括患者的獲取，還包括生物標記檢測的獲取、臨床實驗研究者的經驗、數據互通性、倫理監督、藥物安全監測系統的成熟度以及在日常臨床環境中管理免疫介導毒性的能力。

關鍵國家對免疫腫瘤臨床試驗的見解

美國憑藉其集中的綜合癌症中心、早期臨床試驗機構、分子診斷檢查室、患者支持網路以及支持創新癌症治療研發的監管機制，仍然是免疫腫瘤學臨床試驗的中心樞紐。加拿大擁有強大的學術腫瘤學網路、政府協調的研究基礎設施、腫瘤生物生物銀行庫以及真實世界數據的專業知識。另一方面，墨西哥在主要都市區癌症中心和不斷增強的臨床研究能力的支持下，正擴大其在全球腫瘤學研究中的參與。巴西擁有大規模的癌症患者群體和經驗豐富的試驗中心，是拉丁美洲的主要貢獻者之一，但由於試驗基礎設施、准入途徑和分子檢測可用性方面的區域差異，謹慎選擇試驗中心至關重要。英國在轉化腫瘤學、國家衛生數據資源、早期診斷舉措和適應性臨床試驗專業知識方面仍然保持優勢，而德國則擁有先進的臨床研究基礎設施、腫瘤學專業知識、強大的診斷能力和強大的醫院臨床試驗執行能力。法國透過其綜合癌症研究所、早期准入計劃、國家癌症控制計畫和強大的學術網路支持免疫腫瘤學研究。義大利和西班牙在多中心合作癌症臨床試驗的患者招募、研究者主導的臨床試驗、腫瘤特異性合作研究組活動以及常規臨床環境中的長期隨訪方面繼續發揮著重要作用。俄羅斯歷來具備在大都會圈進行腫瘤臨床試驗的能力，但目前的營運、監管和地緣政治因素必須根據具體情況進行評估。中國是免疫腫瘤學研究最活躍的國家之一，這得益於國內創新的快速發展、大規模的患者群體、完善的醫院網路以及加速抗癌藥物評估的監管改革。印度憑藉其高癌症負擔、不斷擴大的三級癌症治療中心、不斷提高的倫理審查能力以及分子診斷的日益普及，正日益成為重要的戰略合作夥伴，但其運營成功取決於基礎設施、患者隨訪、成本效益和地域可及性差異等方面的改進。日本深厚的腫瘤學專業知識、嚴格的監管要求以及積極參與全球和區域研究（尤其是在橋接數據和特定人群安全性考慮至關重要的領域），為其成功做出了貢獻。澳洲因其早期腫瘤臨床試驗、高效的監管流程、經驗豐富的臨床實驗研究員和高品質的臨床運作而備受推崇。韓國憑藉其先進的醫院系統、關鍵研究中心快速的患者招募、強大的數位基礎設施和先進的轉化研究能力，成為免疫腫瘤學臨床試驗的領先中心。這些國家共同展現了科學基礎、清晰的監管、生物標記的準備、患者准入和臨床運作如何決定免疫腫瘤學臨床試驗的競爭力。

針對免疫腫瘤臨床試驗負責人的實務建議

產業領導者應優先考慮整合生物標記的臨床試驗策略，使作用機制與患者選擇、終點設計、組織要求和伴隨診斷準備保持一致。應盡可能簡化試驗方案，以減輕研究中心的負擔，提高受試者入組率，並支持患者留存，同時確保科學嚴謹性。申辦者和研究夥伴應儘早投入可行性評估，以檢驗各研究中心分子檢測的可用性、組織後勤保障、影像檢查能力、免疫相關不利事件管理、藥物管理系統、臨床實驗藥物處理以及長期追蹤能力。多元化和包容性目標應納入國家、研究中心和受試者招募計劃，並透過社區參與、語言支援、交通途徑支援、看護者參與以及在臨床適宜的情況下採用分散式試驗方案來支持這些目標。應在檢驗的管治架構、偏差測試、稽核追蹤、網路安全措施和人工監督的框架下實施人工智慧和先進的分析技術，以改善試驗配對、監控、資料審查和轉化研究成果。此外，各機構應加強臨床開發、轉化醫學、法規事務、藥物警戒、生物統計、數據管理、臨床運營、診斷團隊和衛生經濟學等領域專家之間的跨職能協作，以確保試驗證據的可靠性、可解釋性和相關性，從而更好地服務於決策者。最後，尤其是在免疫療法朝著治癒性治療和早期癌症治療方向發展的過程中，領導者應規劃如何透過將患者報告結局、真實世界數據、ctDNA監測、影像學後續觀察和治療後安全性監測整合到研發項目中，來確保證據的連續性。

調查方法

本執行摘要採用系統的二手研究途徑編寫，重點關注與免疫腫瘤學臨床試驗相關的、檢驗的、公開可用的、科學可靠的資訊來源。調查方法包括審查主要衛生監管機構的監管指南、臨床試驗註冊資訊、同行評審的腫瘤學文獻、癌症研究機構出版物、衛生機構文件、臨床實踐指南、倫理和多樣性指南，以及與試驗實施、生物標記檢測、人工智慧、患者多樣性、分佈式研究、藥物安全監測和區域臨床研究基礎設施相關的政策材料。研究結果經過定性整合，以識別試驗設計、技術應用、地理參與、運作挑戰、生物標記準備和證據預期方面的一致性模式。本分析避免了不合理的數值預測，也不涉及市場規模估算、市場規模計算、市場佔有率和預測。區域、群體和國家的具體見解從腫瘤學基礎設施、法規環境、臨床實驗能力、患者可及性、主要研究者專業知識、數據管治以及複雜免疫療法試驗的可行性等方面進行解讀。由此產生的框架旨在為參與免疫腫瘤學研究規劃、臨床營運、監管策略和轉化開發的相關人員提供策略決策支援。

結論

免疫腫瘤學臨床試驗正邁入一個更精準、數據密集且全球化的發展階段。查核點抑制劑、細胞療法、雙特異性抗體、癌症疫苗和聯合免疫療法等領域的科學進步，推動了對精密生物標記、適應性試驗設計、高品質病患監測和整合轉化研究的需求。人工智慧、分散式工具和真實世界數據正在提升試驗效率和洞見生成能力，但它們的價值取決於檢驗、管治和倫理實施。區域和國家競爭力日益取決於分子診斷的可及性、經驗豐富的腫瘤研究人員、監管的可預測性、具有代表性的患者招募以及免疫相關毒性的管理能力。對於產業領導者而言，前進的方向清晰明確：設計以生物學證據、患者可近性、操作可行性和證據品質為中心的免疫腫瘤學臨床試驗。那些能夠將科學差異化與全面的患者招募、強大的數據系統、檢驗的數位化工具和全球協調的執行相結合的機構，將更有能力推動癌症免疫療法領域為全球患者帶來意義深遠的創新。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：免疫腫瘤學臨床試驗市場：依治療類型分類

  • 過繼性細胞療法
    • CAR-T
    • NK細胞療法
    • TCR-T
  • 癌症疫苗
    • 樹突細胞疫苗
    • DNA疫苗
    • 胜肽疫苗
  • 查核點抑制劑
    • CTLA-4抑制劑
    • PD-1抑制劑
    • PD-L1抑制劑
  • 細胞激素療法
    • 干擾素療法
      • 干擾素α
      • 干擾素-γ
    • 白細胞介素-2

第8章：免疫腫瘤學臨床試驗市場：依臨床試驗階段分類

  • 第一階段
  • 第二階段
  • 第三階段
  • 第四階段

第9章：免疫腫瘤學臨床試驗市場：依適應症分類

  • 骨髓惡性腫瘤
    • 白血病
    • 淋巴瘤
    • 多發性骨髓瘤
  • 固體癌
    • 乳癌
    • 結腸癌
    • 肺癌
    • 黑色素瘤

第10章：免疫腫瘤學臨床試驗市場：依試驗類型分類

  • 干預試驗
  • 觀察性研究

第11章：免疫腫瘤學臨床試驗市場：以申辦方類型分類

  • 學術機構
  • 生技公司
  • 聯盟
  • 製藥公司

第12章：免疫腫瘤學臨床試驗市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章：免疫腫瘤學臨床試驗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：免疫腫瘤學臨床試驗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • AbbVie Inc
  • Adaptimmune Therapeutics plc
  • Agenus Inc
  • ALX Oncology Holdings Inc
  • Amgen Inc
  • Astellas Pharma Inc
  • AstraZeneca PLC
  • BeiGene Ltd
  • BioNTech SE
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company Ltd
  • Eisai Co Ltd
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences Inc
  • GlaxoSmithKline plc
  • Gritstone Bio Inc
  • Immunocore Holdings plc
  • Incyte Corporation
  • Iovance Biotherapeutics Inc
  • Ipsen SA
  • Johnson & Johnson
  • MacroGenics Inc
  • Merck & Co Inc
  • Moderna Inc
  • Novartis AG
  • Pfizer Inc
  • Regeneron Pharmaceuticals Inc
  • Seagen Inc
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-035590447475

The Immuno-oncology Clinical Trials Market is projected to grow by USD 19.47 billion at a CAGR of 14.81% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.40 billion
Estimated Year [2026] USD 8.32 billion
Forecast Year [2032] USD 19.47 billion
CAGR (%) 14.81%

Immuno-oncology clinical trials are reshaping cancer research by evaluating therapies that activate, restore, or redirect the immune system against tumors, including immune checkpoint inhibitors, cell therapies, cancer vaccines, bispecific antibodies, cytokine-based therapies, and combination regimens. The trial landscape is increasingly defined by biomarker-driven enrollment, adaptive protocol designs, real-world evidence integration, decentralized trial elements, and more sophisticated safety monitoring for immune-related adverse events. Regulatory authorities have reinforced the importance of scientifically justified endpoints, representative patient populations, validated diagnostics, and transparent benefit-risk assessment, particularly as trials move into earlier lines of therapy and perioperative settings. Across oncology, the clinical development agenda is shifting from single-agent evaluation toward rational combinations, tumor-agnostic strategies, minimal residual disease monitoring, and personalized immunotherapy approaches supported by genomic, transcriptomic, proteomic, and immune profiling data. For sponsors, investigators, contract research partners, academic networks, and health systems, success now depends on aligning scientific differentiation with operational excellence, patient access, ethical recruitment, data quality, and regulatory readiness.

Transformative Shifts in the Immuno-oncology Clinical Trials Landscape

The immuno-oncology clinical trials landscape is undergoing transformative change as research moves beyond broad tumor-type enrollment toward precision immunology. Trial protocols increasingly incorporate PD-L1 expression, microsatellite instability, mismatch repair deficiency, tumor mutational burden, homologous recombination repair status, HLA typing, circulating tumor DNA, and immune microenvironment signatures to identify populations most likely to benefit. Combination studies are expanding across checkpoint blockade, targeted therapy, chemotherapy, radiotherapy, antibody-drug conjugates, bispecifics, oncolytic viruses, and adoptive cell therapies, requiring more complex protocol governance and toxicity management. Adaptive and seamless trial designs are being used to accelerate decision-making while maintaining statistical rigor, and master protocols are supporting evaluation of multiple agents, biomarkers, or tumor cohorts within a common infrastructure. Patient-centric trial execution is also gaining momentum through remote consent, telehealth visits, home nursing, electronic patient-reported outcomes, and hybrid monitoring models, particularly for long-duration oncology follow-up. At the same time, regulators and ethics committees are placing greater emphasis on diversity, equitable access, pediatric and geriatric inclusion where appropriate, and post-trial evidence generation. These shifts are making immuno-oncology trials more scientifically ambitious, operationally demanding, and strategically dependent on integrated clinical, translational, digital, and regulatory capabilities.

Cumulative Impact of Artificial Intelligence on Immuno-oncology Trials

Artificial intelligence is increasingly influencing immuno-oncology clinical trials across feasibility assessment, site selection, patient identification, imaging analysis, biomarker discovery, safety surveillance, and trial operations. AI-enabled screening tools can help match patients to eligibility criteria using electronic health records, pathology reports, molecular testing results, and clinical notes, potentially reducing manual prescreening burden while improving recruitment precision. In translational research, machine learning models are being applied to multi-omics datasets, spatial biology, radiomics, and immune repertoire sequencing to identify response signatures and resistance mechanisms. AI-supported medical imaging workflows are helping quantify tumor burden, lesion dynamics, and radiographic patterns relevant to response evaluation, including atypical immune responses such as pseudoprogression. Natural language processing and advanced analytics can also strengthen pharmacovigilance by identifying immune-related adverse event signals from structured and unstructured data. However, the cumulative impact of AI depends on validated algorithms, fit-for-purpose datasets, explainability, cybersecurity, bias mitigation, and compliance with evolving regulatory expectations for digital health technologies and software-based clinical decision support. For immuno-oncology trial stakeholders, AI is best viewed as an augmentation layer that improves speed, consistency, and insight generation, while human clinical judgment, ethical oversight, and protocol-defined evidence standards remain essential.

Key Regional Insights Across Global Immuno-oncology Clinical Trials

Asia-Pacific has become an important region for immuno-oncology clinical trials due to expanding oncology infrastructure, large treatment-naive patient populations, rising molecular diagnostics capacity, and active regulatory modernization in countries such as China, Japan, South Korea, India, and Australia. The region supports a broad spectrum of studies across solid tumors and hematologic malignancies, with growing emphasis on gastric, liver, lung, head and neck, breast, and colorectal cancers, reflecting regional disease burden, screening patterns, and increasing adoption of next-generation sequencing in major cancer centers. North America remains a highly mature environment for immuno-oncology research, supported by comprehensive cancer centers, strong translational science networks, advanced genomic testing access, electronic health record infrastructure, and established regulatory pathways for expedited development where clinical evidence supports unmet medical need. Latin America is gaining relevance through oncology centers in Brazil, Mexico, Argentina, Chile, and Colombia, where diverse patient populations and improving clinical research capabilities support global trial participation, although variability in approvals, reimbursement, molecular testing access, and site resources requires careful operational planning. Europe offers a dense ecosystem of academic oncology groups, harmonized clinical trial regulation across the European Union, and strong capabilities in biomarker science, real-world evidence, and comparative effectiveness research, with the United Kingdom, Germany, France, Italy, and Spain serving as major contributors to multicenter immunotherapy studies. The Middle East is expanding oncology trial capacity through investments in tertiary care, precision medicine programs, cancer registries, and cross-border research collaboration, particularly in Gulf states with advanced hospital infrastructure and national health transformation strategies. Africa remains underrepresented in immuno-oncology trials despite substantial cancer burden and genetic diversity; progress depends on sustained investment in pathology, imaging, molecular diagnostics, ethics review capacity, investigator training, pharmacovigilance systems, and equitable trial access. Across all regions, the most successful immuno-oncology clinical trial programs are those that align protocol complexity with local diagnostic readiness, patient navigation capacity, regulatory timelines, immune-related toxicity management, and long-term follow-up feasibility.

Key Group Insights for Immuno-oncology Clinical Trial Strategy

ASEAN is increasingly relevant to immuno-oncology clinical trials as Singapore, Thailand, Malaysia, Vietnam, Indonesia, and the Philippines strengthen oncology care networks, molecular testing adoption, cancer registry systems, and regional research collaboration, although differences in ethics review processes, infrastructure, reimbursement, and access to advanced diagnostics influence study feasibility. The GCC is building clinical trial capabilities through national cancer strategies, tertiary oncology centers, genomic medicine initiatives, digital health investment, and centralized healthcare modernization, creating opportunities for well-designed immunotherapy trials that address local cancer patterns and improve regional evidence generation. The European Union provides a structured environment for multi-country oncology trials under harmonized clinical trial regulation, supported by strong pharmacovigilance standards, health data governance, privacy protections, and collaborative academic networks; this makes the EU particularly important for biomarker-driven, comparative, and post-authorization evidence studies. BRICS countries collectively represent diverse healthcare systems and large oncology patient populations, with China and India driving substantial trial activity, Brazil and South Africa contributing to geographically diverse recruitment, and Russia maintaining specialized oncology research capacity despite geopolitical and operational complexities that require careful risk assessment. G7 countries continue to influence global immuno-oncology trial standards through advanced regulatory systems, high-volume cancer research institutions, mature health technology assessment frameworks, and leadership in translational oncology, diagnostics, clinical data standards, and real-world data use. NATO member countries overlap significantly with mature North American and European clinical research ecosystems, where trial governance, data security, supply chain resilience, investigational product logistics, and cross-border research coordination are particularly important for complex immuno-oncology studies. Across these groups, the defining success factors are not only patient availability but also biomarker testing access, investigator experience, data interoperability, ethical oversight, pharmacovigilance maturity, and the ability to manage immune-mediated toxicities in routine clinical settings.

Key Country Insights for Immuno-oncology Clinical Trials

The United States remains a central hub for immuno-oncology clinical trials due to its concentration of comprehensive cancer centers, early-phase units, molecular diagnostics laboratories, patient advocacy networks, and regulatory mechanisms that support innovative oncology development. Canada contributes strong academic oncology networks, publicly coordinated research infrastructure, tumor biobanking capabilities, and expertise in real-world evidence, while Mexico offers growing participation in global oncology studies supported by major urban cancer centers and improving clinical research capacity. Brazil is a leading Latin American contributor, with large oncology patient populations and experienced sites, though regional variation in trial infrastructure, access pathways, and molecular testing availability requires careful site selection. The United Kingdom maintains strengths in translational oncology, national health data resources, early diagnosis initiatives, and adaptive trial expertise, while Germany provides advanced clinical research infrastructure, oncology specialization, robust diagnostics capabilities, and strong hospital-based trial execution. France supports immuno-oncology research through integrated cancer institutes, early access mechanisms, national oncology planning, and strong academic networks, and Italy and Spain remain important for multi-center oncology enrollment, investigator-led research, tumor-specific cooperative group activity, and long-term follow-up in routine care settings. Russia has historically contributed oncology trial capacity across large urban centers, although current operational, regulatory, and geopolitical factors must be assessed on a study-by-study basis. China is one of the most active immuno-oncology research environments, supported by rapid expansion in domestic innovation, large patient populations, strengthened hospital networks, and regulatory reforms that have accelerated oncology drug evaluation. India is gaining strategic importance through its high cancer burden, expanding tertiary oncology centers, improving ethics review capacity, and growing molecular diagnostics adoption, while operational success depends on addressing variability in infrastructure, patient follow-up, affordability, and geographic access. Japan brings deep oncology expertise, rigorous regulatory expectations, and strong participation in global and regional studies, particularly where bridging data and population-specific safety considerations are important. Australia is highly valued for early-phase oncology trials, efficient regulatory pathways, experienced investigators, and high-quality clinical operations. South Korea has become a prominent immuno-oncology trial location due to advanced hospital systems, rapid patient recruitment in major centers, strong digital infrastructure, and sophisticated translational research capabilities. Together, these countries illustrate how scientific capability, regulatory clarity, biomarker readiness, patient access, and clinical operations determine the competitiveness of immuno-oncology clinical trial execution.

Actionable Recommendations for Immuno-oncology Trial Leaders

Industry leaders should prioritize biomarker-integrated trial strategies that align mechanism of action with patient selection, endpoint design, tissue requirements, and companion diagnostic readiness. Protocols should be simplified wherever possible to reduce site burden, improve enrollment, and support patient retention without compromising scientific rigor. Sponsors and research partners should invest early in feasibility assessments that verify molecular testing availability, tissue logistics, imaging capacity, immune-related adverse event management, pharmacy readiness, investigational product handling, and long-term follow-up capability at each site. Diversity and inclusion goals should be embedded into country, site, and recruitment planning, supported by community outreach, language access, transportation support, caregiver engagement, and decentralized trial options where clinically appropriate. AI and advanced analytics should be deployed with validated governance frameworks, bias testing, audit trails, cybersecurity controls, and human oversight to improve trial matching, monitoring, data review, and translational insights. Organizations should also strengthen cross-functional collaboration between clinical development, translational medicine, regulatory affairs, pharmacovigilance, biostatistics, data management, clinical operations, diagnostics teams, and health economics specialists to ensure that trial evidence is robust, interpretable, and relevant for decision-makers. Finally, leaders should plan for evidence continuity by integrating patient-reported outcomes, real-world evidence, ctDNA monitoring, imaging follow-up, and post-treatment safety surveillance into development programs, particularly as immunotherapies move into curative-intent and earlier-stage cancer settings.

Research Methodology

This executive summary is developed through a structured secondary research approach focused on verified, publicly available, and scientifically credible sources relevant to immuno-oncology clinical trials. The methodology includes review of regulatory guidance from major health authorities, clinical trial registry information, peer-reviewed oncology literature, cancer research institute publications, health agency documents, clinical practice guidelines, ethics and diversity guidance, and policy materials related to trial conduct, biomarker testing, artificial intelligence, patient diversity, decentralized research, pharmacovigilance, and regional clinical research infrastructure. Insights are synthesized qualitatively to identify consistent patterns in trial design, technology adoption, geographic participation, operational challenges, biomarker readiness, and evidence expectations. The analysis avoids unsupported numerical projections and excludes market estimation, market sizing, market share, and forecasting. Regional, group, and country insights are interpreted through the lenses of oncology infrastructure, regulatory environment, diagnostic capability, patient access, investigator expertise, data governance, and feasibility for complex immunotherapy studies. The resulting framework is intended to support strategic decision-making for stakeholders involved in immuno-oncology research planning, clinical operations, regulatory strategy, and translational development.

Conclusion

Immuno-oncology clinical trials are entering a more precise, data-intensive, and globally distributed phase of development. Scientific progress in checkpoint inhibition, cell therapy, bispecific antibodies, cancer vaccines, and combination immunotherapy is increasing the need for sophisticated biomarkers, adaptive trial designs, high-quality patient monitoring, and integrated translational research. Artificial intelligence, decentralized tools, and real-world evidence are improving trial efficiency and insight generation, but their value depends on validation, governance, and ethical implementation. Regional and country-level competitiveness is increasingly determined by molecular diagnostics access, experienced oncology investigators, regulatory predictability, representative patient recruitment, and the capacity to manage immune-related toxicities. For industry leaders, the path forward is clear: design immuno-oncology trials around biologic rationale, patient accessibility, operational feasibility, and evidence quality. Organizations that combine scientific differentiation with inclusive recruitment, robust data systems, validated digital tools, and globally coordinated execution will be best positioned to advance meaningful cancer immunotherapy innovations for patients worldwide.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Immuno-oncology Clinical Trials Market, by Therapy Type

  • 7.1. Introduction
  • 7.2. Adoptive Cell Therapies
    • 7.2.1. Car-T
    • 7.2.2. Nk Cell Therapy
    • 7.2.3. TCR-T
  • 7.3. Cancer Vaccines
    • 7.3.1. Dendritic Cell Vaccines
    • 7.3.2. Dna Vaccines
    • 7.3.3. Peptide Vaccines
  • 7.4. Checkpoint Inhibitors
    • 7.4.1. Ctla-4 Inhibitors
    • 7.4.2. Pd-1 Inhibitors
    • 7.4.3. Pd-L1 Inhibitors
  • 7.5. Cytokine Therapies
    • 7.5.1. Interferon Therapies
      • 7.5.1.1. Interferon Alpha
      • 7.5.1.2. Interferon Gamma
    • 7.5.2. Interleukin-2

8. Immuno-oncology Clinical Trials Market, by Trial Phase

  • 8.1. Introduction
  • 8.2. Phase I
  • 8.3. Phase II
  • 8.4. Phase III
  • 8.5. Phase IV

9. Immuno-oncology Clinical Trials Market, by Indication

  • 9.1. Introduction
  • 9.2. Hematological Malignancies
    • 9.2.1. Leukemia
    • 9.2.2. Lymphoma
    • 9.2.3. Myeloma
  • 9.3. Solid Tumors
    • 9.3.1. Breast Cancer
    • 9.3.2. Colorectal Cancer
    • 9.3.3. Lung Cancer
    • 9.3.4. Melanoma

10. Immuno-oncology Clinical Trials Market, by Trial Type

  • 10.1. Introduction
  • 10.2. Interventional
  • 10.3. Observational

11. Immuno-oncology Clinical Trials Market, by Sponsor Type

  • 11.1. Introduction
  • 11.2. Academic Institutions
  • 11.3. Biotechnology Companies
  • 11.4. Consortiums
  • 11.5. Pharmaceutical Companies

12. Immuno-oncology Clinical Trials Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Immuno-oncology Clinical Trials Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Immuno-oncology Clinical Trials Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. FPNV Positioning Matrix, 2025
  • 15.3. Market Concentration Analysis, 2025
    • 15.3.1. Concentration Ratio (CR)
    • 15.3.2. Herfindahl Hirschman Index (HHI)
  • 15.4. Recent Developments & Impact Analysis, 2025
  • 15.5. Product Portfolio Analysis, 2025
  • 15.6. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. AbbVie Inc
  • 16.2. Adaptimmune Therapeutics plc
  • 16.3. Agenus Inc
  • 16.4. ALX Oncology Holdings Inc
  • 16.5. Amgen Inc
  • 16.6. Astellas Pharma Inc
  • 16.7. AstraZeneca PLC
  • 16.8. BeiGene Ltd
  • 16.9. BioNTech SE
  • 16.10. Bristol-Myers Squibb Company
  • 16.11. Daiichi Sankyo Company Ltd
  • 16.12. Eisai Co Ltd
  • 16.13. F. Hoffmann-La Roche Ltd
  • 16.14. Gilead Sciences Inc
  • 16.15. GlaxoSmithKline plc
  • 16.16. Gritstone Bio Inc
  • 16.17. Immunocore Holdings plc
  • 16.18. Incyte Corporation
  • 16.19. Iovance Biotherapeutics Inc
  • 16.20. Ipsen SA
  • 16.21. Johnson & Johnson
  • 16.22. MacroGenics Inc
  • 16.23. Merck & Co Inc
  • 16.24. Moderna Inc
  • 16.25. Novartis AG
  • 16.26. Pfizer Inc
  • 16.27. Regeneron Pharmaceuticals Inc
  • 16.28. Seagen Inc
  • 16.29. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 23. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ADOPTIVE CELL THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ADOPTIVE CELL THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ADOPTIVE CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CAR-T MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CAR-T MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CAR-T MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NK CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NK CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NK CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TCR-T MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TCR-T MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TCR-T MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CANCER VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANCER VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DENDRITIC CELL VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DENDRITIC CELL VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DENDRITIC CELL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DNA VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DNA VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DNA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PEPTIDE VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PEPTIDE VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PEPTIDE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CHECKPOINT INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CHECKPOINT INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CTLA-4 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CTLA-4 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CTLA-4 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PD-1 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PD-1 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PD-1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PD-L1 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PD-L1 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CYTOKINE THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CYTOKINE THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CYTOKINE THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INTERFERON THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INTERFERON THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INTERFERON THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INTERFERON ALPHA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INTERFERON ALPHA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INTERFERON ALPHA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL INTERFERON GAMMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INTERFERON GAMMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INTERFERON GAMMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INTERLEUKIN-2 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INTERLEUKIN-2 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INTERLEUKIN-2 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PHASE I MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PHASE I MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PHASE I MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PHASE II MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PHASE II MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PHASE II MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PHASE III MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PHASE III MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PHASE III MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PHASE IV MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PHASE IV MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PHASE IV MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL LEUKEMIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL LEUKEMIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL LEUKEMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL LYMPHOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL LYMPHOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL LYMPHOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MYELOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL MYELOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL MYELOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL SOLID TUMORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL SOLID TUMORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL SOLID TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL COLORECTAL CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL COLORECTAL CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL COLORECTAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL MELANOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL MELANOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL MELANOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL INTERVENTIONAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL INTERVENTIONAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL INTERVENTIONAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL OBSERVATIONAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL OBSERVATIONAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL OBSERVATIONAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ACADEMIC INSTITUTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ACADEMIC INSTITUTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ACADEMIC INSTITUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CONSORTIUMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL CONSORTIUMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CONSORTIUMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 210. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 212. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 213. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 214. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 215. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 216. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 217. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 218. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 219. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 220. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. G7 IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 249. G7 IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. G7 IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 251. G7 IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 252. G7 IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 253. G7 IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 254. G7 IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 255. G7 IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 256. G7 IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 257. G7 IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 258. G7 IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 259. G7 IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. G7 IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. NATO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 262. NATO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. NATO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 264. NATO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 265. NATO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 266. NATO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 267. NATO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 268. NATO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 269. NATO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 270. NATO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 271. NATO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 272. NATO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. NATO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 289. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 291. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 292. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 293. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 294. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 295. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 296. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 297. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 298. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 299. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 302. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 303. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 304. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 305. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 306. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 307. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 308. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 309. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 310. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 311. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 312. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 313. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 314. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 315. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 316. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 317. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 318. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 319. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 320. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 321. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 322. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 323. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 324. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 325. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 326. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 327. UNITED KINGDOM IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 328. UNITED KINGDOM IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 329. UNITED KINGDOM IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 330. UNITED KINGDOM IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 331. UNITED KINGDOM IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY